Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 10/2015

01-10-2015 | Original Paper

Cost and Threshold Analysis of Positive Charge, a Multi-site Linkage to HIV Care Program in the United States

Authors: Jeeyon Janet Kim, Cathy Maulsby, Rose Zulliger, Kriti Jain, Vignetta Charles, Maura Riordan, Melissa Davey-Rothwell, David R. Holtgrave, The Positive Charge Intervention Team

Published in: AIDS and Behavior | Issue 10/2015

Login to get access

Abstract

Positive Charge (PC) is a linkage to HIV care initiative implemented by AIDS United with sites in New York, Chicago, Louisiana, North Carolina, and the San Francisco/Bay Area. This study employed standard methods of cost and threshold analyses, as recommended by the US Panel on Cost-effectiveness in Health and Medicine, to calculate cost-saving and cost effective thresholds of the initiative. The overall societal cost of the linkage to care programs ranged from $48,490 to $370,525. The study found that PC’s five unique evidence-based linkage to care programs have relatively low costs per client served and highly achievable cost-saving and cost-effectiveness thresholds. The findings from this study suggest that HIV linkage to care programs have the potential to be a highly productive use of public health resources.
Appendix
Available only for authorised users
Literature
1.
Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2012. HIV Surveillance Supplemental Report 2014;19(3).
2.
3.
Centers for Disease Control and Prevention. HIV Surveillance Report. 2012;24.
4.
Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800.PubMedCentralCrossRefPubMed
5.
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11):1512–20.PubMedCentralCrossRefPubMed
6.
Hall HI, Frazier EL, Rhodes P, Holtgrave DR, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.CrossRefPubMed
7.
Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359(9318):1635–42.CrossRefPubMed
8.
Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331(7530):1431–7.PubMedCentralCrossRefPubMed
9.
Walker D. Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy Plan. 2003;18:4–17.CrossRefPubMed
10.
Kessler J, Myers JE, Nucifora KA, Mensah N, Kowalski A, et al. Averting HIV infections in New York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies. PLoS One. 2013;8(9):e73269.PubMedCentralCrossRefPubMed
11.
Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153:778–89.PubMedCentralCrossRefPubMed
12.
Weaver MR, Conover CJ, Proescholdbell RJ, Arno PS, Ang A, Uldall KK, Ettner SL. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders. J Ment Health Policy Econ. 2009;12(1):33–46.PubMed
13.
Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, Del Rio C, Strathdee S, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. Aids. 2005;19(4):423–31.CrossRefPubMed
14.
Gold MR, Seigel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
15.
Holtgrave DR. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Publishing Corporation; 1998.CrossRef
16.
Holtgrave DR, Briddell K, Little E, Bendixen AV, Hooper M, Kidder DP, et al. Cost and threshold analysis of housing as an HIV prevention intervention. AIDS Behav. 2007;11(2):162–6.CrossRefPubMed
17.
18.
Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. JAIDS. 1997;16(1):54–62.PubMed
19.
Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, DelRio C, Kamimoto L, Kellerman SE. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. JAIDS. 2006;43(4):451–7.PubMed
20.
Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2011;15(7):917–28.CrossRef
21.
Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current Human Immunodeficiency Virus care in the United States. Med Care. 2006;44(11):990–7.CrossRefPubMed
22.
Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB. Lifetime costs and QALYs saved from HIV prevention in the test and treat era letter to the editor. JAIDS. 2013;64(2):e15–8.PubMed
23.
Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45(Suppl 4):S248–54.PubMedCentralCrossRefPubMed
24.
Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions. JAIDS. 2004;37:1404–14.PubMed
25.
White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington: White House Office of National AIDS Policy; 2010.
26.
Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, Fagan JL, Lansky A, Mermin JK. Human Immunodeficiency Virus Transmission at Each Step of the Care Continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed
27.
28.
29.
Paltiel AD, Stinnett AA. Resource allocation and the funding of HIV prevention. In: Holtgrave DR, editor. Handbook of economic evaluation of HIV prevention programs. New York: Plenum Press; 1998. p. 135–52.CrossRef
30.
Rauner MS, Brandeau ML. AIDS policy odeling for the 21st century: an overview of key issues. Health Care Manag Sci. 2001;4:165–80.CrossRefPubMed
31.
Holtgrave DR. HIV prevention, cost-utility analysis, and race/ethnicity: methodological considerations and recommendations. Med Decis Making. 2004;24(2):181–91.CrossRefPubMed
32.
Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables.
Metadata
Title
Cost and Threshold Analysis of Positive Charge, a Multi-site Linkage to HIV Care Program in the United States
Authors
Jeeyon Janet Kim
Cathy Maulsby
Rose Zulliger
Kriti Jain
Vignetta Charles
Maura Riordan
Melissa Davey-Rothwell
David R. Holtgrave
The Positive Charge Intervention Team
Publication date
01-10-2015
Publisher
Springer US
Published in
AIDS and Behavior / Issue 10/2015
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-015-1124-9

Other articles of this Issue 10/2015

AIDS and Behavior 10/2015 Go to the issue

Original Paper

Acceptability and Preliminary Efficacy of a Tailored Online HIV/STI Testing Intervention for Young Men who have Sex with Men: The Get Connected! Program

Original Paper

Mediation Analysis of an Effective Sexual Health Promotion Intervention for Spanish Adolescents

Original Paper

The Use of Mystery Shopping for Quality Assurance Evaluations of HIV/STI Testing Sites Offering Services to Young Gay and Bisexual Men

Original Paper

Feasibility of Using an iPod Touch Device and Acceptability of a Stigma Reduction Intervention with HIV-Infected Women in the Deep South

Original Paper

Effectiveness of Peer Support on Care Engagement and Preventive Care Intervention Utilization Among Pre-antiretroviral Therapy, HIV-Infected Adults in Rakai, Uganda: A Randomized Trial

Substantive Review

Effectiveness of Interventions Promoting HIV Serostatus Disclosure to Sexual Partners: A Systematic Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits